Taking peoplePhase 1
Tests the safety of RO7568282 in healthy people and people with Parkinson's disease
Tests the drug RO7568282 for safety in adults with Parkinson's disease and healthy adults.
Key facts
- Who runs it
- F. Hoffmann-La Roche AG
- Where
- Goteborg, Huddinge, Lund, and Uppsala, SwedenSee the 4 sitesAlso in 2 other countries, 6 sites
- Trial code
- Registry title
- A study to test the biological properties of RO7568282 and whether it is safe in healthy participants and participants with Parkinson’s disease.
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 150 people, planned
- Started
- 9 Sept 2024
- Expected to end
- 11 Apr 2028
- Type of study
- Interventional
- Record updated
- 20 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for healthy adults and adults with Parkinson's disease, to study how RO7568282 acts in the body and whether it is safe.
- Age
- 18 years or older
- Sex
- All sexes can join
Where in Sweden
Also in 2 other countries, 6 sites
- Sahlgrenska University Hospital-Vaestra GoetalandsregionenGoteborg, SwedenNot yet recruiting
- Karolinska University HospitalHuddinge, SwedenNot yet recruiting
- Region Skane Skanes UniversitetssjukhusLund, SwedenNot yet recruiting
- CTC Clinical Trial Consultants ABUppsala, SwedenNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Tests the safety of RO7568282 in healthy people and people with Parkinson's diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 20 October 2026